Amniotic fluid index

From WikiMD's WELLNESSPEDIA

Amniotic Fluid Index (AFI) is a quantitative estimate of amniotic fluid volume and is an integral part of the antenatal care procedure. It is a significant aspect of fetal health and well-being.

Overview[edit]

The Amniotic Fluid Index is a score calculated from the depths of fluid in four quadrants of the pregnant uterus. The depth of the fluid in each quadrant is measured, and the sum of these four measurements is the AFI. The AFI helps to determine if there are potential issues with the pregnancy, such as oligohydramnios (low levels of amniotic fluid) or polyhydramnios (high levels of amniotic fluid).

Measurement[edit]

The AFI is typically measured using ultrasound during the second and third trimesters of pregnancy. The uterus is divided into four quadrants, and the vertical depth of the deepest, unobstructed, fluid-filled area in each quadrant is measured. The sum of these four measurements gives the AFI.

Interpretation[edit]

The normal range for the AFI is 5-25 cm. An AFI < 5cm is considered oligohydramnios, and an AFI > 25cm is considered polyhydramnios. Both conditions can pose risks to the fetus and may require further monitoring or intervention.

Clinical Significance[edit]

The AFI is an important tool in assessing fetal well-being. Abnormal AFI levels can indicate potential complications such as intrauterine growth restriction (IUGR), preterm birth, and perinatal mortality. It is also used in the management of high-risk pregnancies, such as those with diabetes mellitus or hypertension.

See Also[edit]


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.